Manufacturing

Articles

Under the terms of the acquisition, OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies, WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit.

WuXi AppTec Acquires OXGENE to Increase Cell and Gene Therapy Offerings

The site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization.

Celonic to Establish New Cell and Gene Therapy Production Site in Switzerland

The expansion, to be completed in April 2021 aims to increase the CDMO’s viral-vector production capacity in Spain.

VIVEbiotech to Expand Facilities for Lentiviral-Vector Manufacturing

The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.

Novartis and the Bill & Melinda Gates Foundation Team Up to Develop Gene Therapy for Sickle Cell Disease

The acquisition will allow Charles River to expand its cell and gene therapy development, testing, and manufacturing capabilities, while adding to its existing portfolio of non-clinical capabilities.

Charles River to Acquire Cognate BioServices for $875 Million

Catalent will offer materials from its gene therapy facilities in Maryland to support IND-enabling studies and a Phase I/II clinical trial of the product.

Catalent and Decibel Team Up to Develop Gene Therapy for Congenital Hearing Loss

Biotechnology company, Polyplus-transfection, has started construction of a new facility in France to meet growth in the cell and gene therapy market.

Polyplus-transfection Commences Build of New Facility

Evozyne’s evolution-based protein design technology will be used to research and develop proteins that could be used in the next generation of gene therapies.

Takeda and Evozyne Enter into Gene Therapy Collaboration 

Through the acquisition, Lilly will have access to Prevail’s portfolio of clinical-stage and preclinical neuroscience assets.

Eli Lilly Completes $1.5 Billion Acquisition of Prevail Therapeutics

Paul S. Larson, MD, paul.larson@ucsf.edu, is professor and vice-chair of Neurological Surgery at the University of California San Francisco, chief of Neurosurgery at the San Francisco Veterans Affairs Medical Center, and surgical director of the Parkinson’s Disease Research, Education and Clinical Center.

Leveraging real-time MRI guidance for intracranial gene therapy administration potentially improves efficacy and outcomes.

Manufacturing, Gene Therapies